Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polyethylene glycol loxenatide for diabetic nephropathy
ChiCTR2300070919Phase 4Not yet recruiting
- Sponsor
- Sunshine Union Hospital
- Start
- Apr 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of polyethylene glycol loxenatide in diabetic glomerulosclerosis (2 arms), sponsored by Sunshine Union Hospital. Primary endpoint: Urinary albumin-to-creatinine ratio. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on ChiCTR2300070919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070919.